Top

World Journal of Urology

Published in:

01-06-2012 | Topic paper

Androgen receptor co-activators in the regulation of cellular events in prostate cancer

Authors: Zoran Culig, Frédéric R. Santer

Published in: World Journal of Urology | Issue 3/2012

Abstract

Objectives

Androgen receptor (AR) action in benign and malignant tissue is potentiated by a number of co-regulatory proteins that may interact with one or more receptor domains. With improvement of research methodologies, it became possible to detect a number of co-activators whose expression is increased in prostate cancer tissue.

Methods

Manuscripts describing prostate cancer–relevant regulation of cellular events by co-activators are selected and summarized.

Results

AR co-activators may regulate histone modification, proteasomal degradation, chaperones, sumoylation, chromatin remodeling, and cytoskeleton. Some of them (TIF-2) are up-regulated by androgens, whereas the expression of others increases during androgen ablation (p300, CBP, and Tip60). Most co-factors are important for the stimulation of cellular proliferation, although in some cases (ART-27), they act as tumor suppressors and are deleted in prostate cancer tissue. In addition to stimulating AR, some co-activators suppress apoptosis in prostate cancer cells that do not express the AR (p300 and SRC-3). It was recently shown that the inhibition of p300 slows down proliferation, stimulates apoptosis, and inhibits migration and invasion.

Conclusions

Co-factors whose down-regulation results in the alterations of multiple cellular functions may be valid targets for novel therapies in advanced prostate cancer.

Heemers H, Tindall DJ (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 28:778–808PubMedCrossRef

Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci USA 93:5517–5521PubMedCrossRef

Miyamoto H, Yeh S, Wilding G et al (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 95:7379–7384PubMedCrossRef

Miyamoto H, Yeh S, Lardy H et al (1998) Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95:11083–11088PubMedCrossRef

Nessler-Menardi C, Jotova I, Culig Z et al (2000) Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 45:124–131PubMedCrossRef

Halkidou K, Gnanapragasam VJ, Mehta PB et al (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 22:2466–2477PubMedCrossRef

Montogmery BT, Young CY, Bilhartz DL et al (1992) Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 21:63–73CrossRef

Kyprianou N, Isaacs JT (1989) Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515–1522PubMedCrossRef

Heemers HV, Regan KM, Dehm SM et al (2007) Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role of serum response factor in prostate cancer. Cancer Res 67:10592–10599PubMedCrossRef

10.

Agoulnik IU, Vaid A, Nakka M et al (2006) Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 66:10594–10602PubMedCrossRef

11.

Gao T, Brantley K, Bolu E et al (1999) RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays. Mol Endocrinol 13:1645–1656PubMedCrossRef

12.

Comuzzi B, Nemes C, Schmidt S et al (2004) The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 204:159–166PubMedCrossRef

13.

Heemers H, Sebo TJ, Debes JD et al (2007) Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 67:3422–3430PubMedCrossRef

14.

Shiota M, Yokomizo A, Masubuchi D et al (2010) Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate 70:540–544PubMed

15.

Gregory CW, Fei X, Pongula LA et al (2004) Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem 279:7119–7130PubMedCrossRef

16.

Craft N, Shostak Y, Carey M et al (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280–285PubMedCrossRef

17.

Feng S, Tang Q, Sun M et al (2009) Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther 8:665–671PubMedCrossRef

18.

Debes JD, Schmidt LJ, Huang H et al (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632–5636PubMed

19.

Culig Z, Steiner H, Bartsch G et al (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497–505PubMedCrossRef

20.

Malinowska K, Neuwirt H, Cavarretta IT et al (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155–169PubMedCrossRef

21.

Hobisch A, Eder IE, Putz et al (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58:4640–4645PubMed

22.

Debes JD, Comuzzi B, Schmidt LJ et al (2005) p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65:5965–5973PubMedCrossRef

23.

Comuzzi L, Lambrinidis L, Rogatsch H et al (2003) The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol 162:233–241PubMedCrossRef

24.

Gong J, Zhu J, Goodman OB Jr et al (2006) Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene 25:2011–2021PubMedCrossRef

25.

Agoulnik IU, Vaid A, Bingman WE 3rd et al (2005) Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 65:7959–7967PubMed

26.

Gnanapragasam VJ, Leung HY, Pullmood AS et al (2001) Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer 85:1928–1936PubMedCrossRef

27.

Axlund SD, Lambert JR, Nordeen SK (2010) HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes. Mol Cancer Res 8:1643–1655PubMedCrossRef

28.

Miyajima N, Maruyama S, Bohgaki M et al (2008) TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. Cancer Res 68:3486–3494PubMedCrossRef

29.

Xu K, Shimelis H, Linn DE et al (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15:270–282PubMedCrossRef

30.

Solit DB, Scher HI, Rosen N et al (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30:709–716PubMedCrossRef

31.

Saporita AJ, Ai J, Wang Z (2007) The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 67:509–520PubMedCrossRef

32.

Schulz WA, Alexa A, Jung V et al (2007) Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer 6:14PubMedCrossRef

33.

Nishimura K, Ting HJ, Harada Y et al (2003) Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 63:4888–4894PubMed

34.

Van de Wijngaart DJ, Dubbink HJ, Molier M et al (2011) Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection. Prostate 71:241–253PubMedCrossRef

35.

Wang Y, Kreisberg JI, Bedolla RG et al (2007) A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4–2 prostate cancer cells. Oncogene 26:6061–6070PubMedCrossRef

36.

Castoria G, DÁmato L, Ciociola A et al (2011) Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One 16:e17218CrossRef

37.

Ting HJ, Yeh S, Nishimura K et al (2002) Supervillin associates with androgen receptor and modulates its transcriptional activity. Proc Natl Acad Sci USA 99:661–666PubMedCrossRef

38.

Yamamoto A, Hashimoto Y, Kohri K et al (2000) Cyclin E as a coactivator of the androgen receptor. J Cell Biol 150:873–880PubMedCrossRef

39.

Petre-Draviam CE, Cook SL, Burd CJ et al (2003) Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 63:4903–4913PubMed

40.

Burd CJ, Petre CE, Morey LM et al (2006) Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 103:2190–2195PubMedCrossRef

41.

Nwachukwu JC, Mita P, Ruoff R et al (2009) Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res 69:3140–3147PubMedCrossRef

42.

Heitzer MD, DeFranco DB (2006) Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 66:7326–7333PubMedCrossRef

43.

Ligr M, Li Y, Zou X et al (2010) Tumor suppressor function of androgen receptor coactivator ARA70alpha in prostate cancer. Am J Pathol 176:1891–1900PubMedCrossRef

44.

Peng Y, Chen F, Melamed J et al (2008) Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer. Proc Natl Acad Sci USA 105:5236–5241PubMedCrossRef

45.

Zhou G, Hashimoto Y, Kwak I et al (2003) Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742–7755PubMedCrossRef

46.

Yan J, Yu CT, Ozen M et al (2006) Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 66:11039–11046PubMedCrossRef

47.

Yan J, Erdem H, Li R et al (2008) Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res 68:5460–5468PubMedCrossRef

48.

Santer FR, Höschele PP, Oh SJ et al (2011) Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 10:1644–1655PubMedCrossRef

Title: Androgen receptor co-activators in the regulation of cellular events in prostate cancer
Authors: Zoran Culig
Frédéric R. Santer
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 3/2012
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-011-0797-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Androgen receptor co-activators in the regulation of cellular events in prostate cancer

Abstract

Objectives

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2012

NF-κB signaling in prostate cancer: A promising therapeutic target?

Age-specific PCA3 score reference values for diagnosis of prostate cancer

Prospective comparison of short-term functional outcomes obtained after pure laparoscopic and robot-assisted laparoscopic sacrocolpopexy

AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells

Enhanced urothelial expression of human chorionic gonadotropin beta (hCGβ) in bladder pain syndrome/interstitial cystitis (BPS/IC)

ID4 is frequently downregulated and partially hypermethylated in prostate cancer